Cai Xiaoling, Yang Wenjia, Chen Yifei, Gao Xueying, Zhou Lingli, Zhang Simin, Han Xueyao, Ji Linong
a Endocrine & Metabolism Department , Peking University People's Hospital , Beijing , China.
Expert Opin Pharmacother. 2016 Aug;17(12):1591-8. doi: 10.1080/14656566.2016.1202921. Epub 2016 Jul 4.
To compare the effects of blood glucose lowering regimens in groups of patients categorized by baseline age and diagnosed age.
Placebo-controlled randomized trials in type 2 diabetes patients with a study length ≥12 weeks were included.
A total of 246 trials were included. HbA1c changes from baseline corrected by placebo were comparable in sulfonylurea treatment between older and younger patients' groups (weighted mean difference (WMD), -1.28% vs -0.92%, p > 0.05). Treatment with metformin between groups resulted in a comparable change in HbA1c levels (WMD, -0.97% vs -1.23%, p > 0.05). Treatment with α-glucosidase inhibitor (WMD, -0.68% vs -0.67%, p > 0.05), treatment with thiazolidinedione (WMD, -0.74% vs -1.01%, p > 0.05), treatment with DPP-4 inhibitors (WMD, -0.67% vs -0.67%, p > 0.05), and treatment with SGLT2 inhibitors (WMD, -0.54% vs -0.67%, p > 0.05) between groups also resulted in comparable HbA1c changes. Treatment with GLP-1 analogs between groups in HbA1c changes were also comparable (p > 0.05). Regression analysis indicated that the baseline age or diagnosed age was not associated with the HbA1c changes from baseline.
In each hypoglycemic treatment, the baseline age or diagnosed age was not associated with the HbA1c changes from baseline.
比较按基线年龄和确诊年龄分类的患者组中降血糖方案的效果。
纳入研究时长≥12周的2型糖尿病患者的安慰剂对照随机试验。
共纳入246项试验。老年患者组和年轻患者组使用磺脲类药物治疗时，经安慰剂校正后的糖化血红蛋白（HbA1c）自基线的变化相当（加权平均差（WMD），-1.28%对-0.92%，p>0.05）。两组间使用二甲双胍治疗导致HbA1c水平变化相当（WMD，-0.97%对-1.23%，p>0.05）。使用α-葡萄糖苷酶抑制剂治疗（WMD，-0.68%对-0.67%，p>0.05）、使用噻唑烷二酮类药物治疗（WMD，-0.74%对-1.01%，p>0.05）、使用二肽基肽酶-4（DPP-4）抑制剂治疗（WMD，-0.67%对-0.67%，p>0.05）以及使用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂治疗（WMD，-0.54%对-0.67%，p>0.05）时，两组间HbA1c变化也相当。两组间使用胰高血糖素样肽-1（GLP-1）类似物治疗时HbA1c变化也相当（p>0.05）。回归分析表明，基线年龄或确诊年龄与HbA1c自基线的变化无关。
在每种降糖治疗中，基线年龄或确诊年龄与HbA1c自基线的变化无关。
